Phase II study of Kynurenic acid (FS2) prevention of post-surgical scar formation

Trial Profile

Phase II study of Kynurenic acid (FS2) prevention of post-surgical scar formation

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs Kynurenic acid (Primary)
  • Indications Scars
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Feb 2018 New trial record
    • 16 Feb 2018 According to a BirchBioMed media release, the company got clearance by Health Canada to begin a phase II clinical trial of FS2.
    • 16 Feb 2018 Dr. Anthony Papp, M.D. Ph.D will be principal investigator for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top